ArticleAvicenna journal of medical biotechnology
Plant-Based Recombinant Vaccines for Foot-and-Mouth Disease: A Meta-Synthesis.
Article in Avicenna journal of medical biotechnology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Foot-and-Mouth Disease (FMD) remains a persistent global threat to livestock health and food security, particularly in endemic and resource-constrained regions. Conventional inactivated vaccines pose several challenges-including biosafety risks and dependence on cold-chain logistics. These limitations have prompted growing interest in plant-based recombinant vaccine platforms as innovative, scalable, and safer alternatives for FMD prevention. Methods: This study employed a qualitative meta-synthesis approach, guided by the Barroso-Sandelowski method, to systematically extract, interpret, and integrate findings from 35 peer-reviewed empirical studies published between 2000 and 2025. The selected studies focused on the development and evaluation of plant-made vaccines targeting FMD. Thematic coding and interpretive synthesis were applied to identify recurrent patterns, challenges, and opportunities across the literature. Results: The analysis yielded four dominant themes: (1) Platform Diversity: A variety of plant and algal expression hosts were used through transient or stable transformation systems, (2) Immunization Routes: Oral vaccination was noted for its logistical advantages and potential for mass immunization, though often requiring adjuvants to enhance immunogenicity, (3) Scale-Up Challenges: Key barriers included low recombinant protein yields, heterogeneity in post-translational modifications and high variability between production batches and (4) Regulatory Readiness: Despite encouraging pre-clinical data, most candidates have not progressed beyond experimental stages. Conclusion: Plant-based recombinant vaccines represent a promising frontier in the fight against FMD, offering novel avenues for safer, more accessible immunization strategies. However, their transition from bench to field remains hindered by technical limitations in expression and purification, as well as institutional and regulatory gaps.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.